HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
XAIR
Beyond Air, Inc.
There isn't enough reported data to score XAIR yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
XAIR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Unavailable |
XAIR's revenue is currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
XAIR PE Valuation
XAIR has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
XAIR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect XAIR's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
XAIR has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus XAIR down 150%.
XAIR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2024 | -$424.00 | +$429.13 |
| Q3 2024 | -$564.00 | +$261.13 |
| Q2 2024 | -$656.00 | +$125.13 |
| Q1 2024 | -$728.00 | +$21.13 |
| Q4 2023 | -$853.13 | -$74.83 |
| Q3 2023 | -$825.13 | -$102.83 |
| Q2 2023 | -$781.13 | -$74.83 |
| Q1 2023 | -$749.13 | -$66.83 |
XAIR is still losing money, but far less than before: $424.00 per share over the past year, against $853.13 at its worst in late 2023.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
XAIR has the stronger quarterly revenue trend. Revenue is up 49% for HIMS versus up 145% for XAIR.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
XAIR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2025 | $1.2M | +145% |
| Q4 2024 | $1.1M | +174% |
| Q3 2024 | $798K | +234% |
| Q2 2024 | $683K | +1058% |
| Q4 2020 | $148.8K | -53% |
XAIR's revenue has grown year over year for six quarters in a row: $1M last quarter, up 145% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2025 | -623% | +2065 points |
| Q4 2024 | -1022% | +3317 points |
| Q3 2024 | -1608% | +5729 points |
| Q2 2024 | -1988% | +24919 points |
| Q1 2024 | -2688% | N/A |
| Q4 2023 | -4338% | N/A |
| Q3 2023 | -7337% | N/A |
| Q2 2023 | -26907% | N/A |
XAIR's operating margin was −623% last quarter, up 2065 points from the same quarter a year ago, near the top of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over XAIR on cash generation, producing positive trailing cash flow while its opponent burns cash.
XAIR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.3M | -$1.6M |
| Q2 2026 | -$5.2M | -$430K |
| Q1 2026 | -$5.5M | +$3M |
| Q4 2025 | -$4.3M | +$4M |
| Q3 2025 | -$4.7M | +$9.8M |
| Q2 2025 | -$4.7M | +$8.1M |
| Q1 2025 | -$8.5M | +$4.2M |
| Q4 2024 | -$8.3M | +$6.9M |
XAIR has burned cash in almost every quarter: −$21M over the past year, against −$26M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over XAIR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
XAIR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +188% | +1.4M shares |
| 1 year | +729% | +1.8M shares |
| 3 years | +2679% | +2M shares |
| 5 years | +4757% | +2M shares |
XAIR has 2M diluted shares, up 729% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2020 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
XAIR Net Leverage
XAIR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
XAIR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.2 | Oversold |
| Stochastic | 4.0 | Oversold |
XAIR's weekly RSI is 27 (oversold) and its Stochastic is 4 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
XAIR PE vs Healthcare Sector
XAIR has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
XAIR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.35 | 6% below |
| 20 week MA | $4.18 | 47% below |
| 50 week MA | $11.3 | 80% below |
| 100 week MA | $48.1 | 95% below |
| 200 week MA | $542.0 | 100% below |
XAIR is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over XAIR on returns for 2026, with the stronger performance.
XAIR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1,752.0 | $2,084.0 | +19% |
| 2021 | $2,084.0 | $3,916.0 | +88% |
| 2022 | $3,916.0 | $2,496.0 | -36% |
| 2023 | $2,496.0 | $784.0 | -69% |
| 2024 | $784.0 | $176.0 | -78% |
| 2025 | $176.0 | $15.0 | -91% |
| 2026 YTD | $15.0 | $2.21 | -85% |
XAIR has finished four years in a row lower, and it's down 85% so far in 2026.